MedTrace Logo

Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

NCT05667064 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2026-03-10

No results posted yet for this study

Summary

This investigation will be conducted to collect information of safety in patients with unresectable hepatocellular carcinoma (HCC) treated with the combination therapy of IMJUDO 25 mg, 300 mg and IMFINZI Intravenous Infusion 120 mg, 500 mg or with IMFINZI monotherapy under actual use in the post-marketing setting.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Toshimitsu Tokimoto · AstraZeneca KK

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-09
Primary Completion
2025-07-21
Completion
2025-07-21

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05667064 on ClinicalTrials.gov